Format

Send to

Choose Destination
EMBO J. 2001 Dec 17;20(24):6969-78.

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.

Author information

1
Forschungszentrum Karlsruhe, Institute of Toxicology and Genetics, H.-v.-Helmholtz-Platz 1, D-76344 Eggenstein, Germany. martin.goettlicher@itg.fzk.de

Abstract

Histone deacetylases (HDACs) play important roles in transcriptional regulation and pathogenesis of cancer. Thus, HDAC inhibitors are candidate drugs for differentiation therapy of cancer. Here, we show that the well-tolerated antiepileptic drug valproic acid is a powerful HDAC inhibitor. Valproic acid relieves HDAC-dependent transcriptional repression and causes hyperacetylation of histones in cultured cells and in vivo. Valproic acid inhibits HDAC activity in vitro, most probably by binding to the catalytic center of HDACs. Most importantly, valproic acid induces differentiation of carcinoma cells, transformed hematopoietic progenitor cells and leukemic blasts from acute myeloid leukemia patients. More over, tumor growth and metastasis formation are significantly reduced in animal experiments. Therefore, valproic acid might serve as an effective drug for cancer therapy.

PMID:
11742974
PMCID:
PMC125788
DOI:
10.1093/emboj/20.24.6969
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center